Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | ARG1 | P05089 | 1/20 | 0.32 |
| ▸ | ARG2 | P78540 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 2/20 | 0.30 |
| ▸ | HTR1B | P28222 | 2/20 | 0.30 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3150458 | 1.00 | ALDH1A1 (0.41) | ALDH1A1HRH3ARG1ARG2HTR1A | |
| SCHEMBL23740290 | 1.00 | ALDH1A1 (0.41) | ALDH1A1HRH3ARG1ARG2HTR1A | |
| SCHEMBL21742288 | 1.00 | ALDH1A1 (0.41) | ALDH1A1HRH3ARG1ARG2HTR1A | |
| SCHEMBL15183780 | 1.00 | ALDH1A1 (0.41) | ALDH1A1HRH3ARG1ARG2HTR1A | |
| SCHEMBL10226529 | 0.97 | ALDH1A1 (0.37) | ALDH1A1HRH3ARG1ARG2 | |
| SCHEMBL4567658 | 0.88 | — | — | |
| SCHEMBL24808630 | 0.82 | KDM4E (0.40) | ALDH1A1 | |
| SCHEMBL29926359 | 0.80 | HRH3 (0.47) | HRH3HTR1AHTR1BHTR1D | |
| SCHEMBL30495486 | 0.80 | HRH3 (0.35) | HRH3HTR1AHTR1BHTR1D | |
| SCHEMBL4451768 | 0.80 | HRH3 (0.47) | HRH3HTR1AHTR1BHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646419-B1 | METHOD FOR PREPARING ROSUVASTATIN SALTS | EGIS GYÓGYSZERGYÁR NYILVÁNOSAN MÛKÖDÕ RÉSZVÉNYTÁRSASÁG (HU) | 2017-10-18 | — | — | EP | disclosed |
| US-9040696-B2 | Method for preparing rosuvastatin salts | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2015-05-26 | — | — | US | disclosed |
| EP-2593427-B1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| US-20130281694-A1 | METHOD FOR PREPARING ROSUVASTATIN SALTS | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENY-TARSASAG (HU) | 2013-10-24 | — | — | US | disclosed |
| EP-2646419-A2 | METHOD FOR PREPARING ROSUVASTATIN SALTS | Egis Gyógyszergyár Nyilvánosan Müködö Részvény-Társaság (HU) | 2013-10-09 | — | — | EP | disclosed |
| EP-2593427-A1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012073054-A2 | METHOD FOR PREPARING ROSUVASTATIN SALTS | EGIS GYÓGYSZERGYÁR NYILVÁNOSAN MÚKÖDÓ RÉSZVÉNY-TÁRSASÁG (HU) | 2012-06-07 | — | — | WO | disclosed |
| EP-2424860-A1 | HETEROARYLTHIOMETHYL PYRIDINE DERIVATIVE | MSD K.K. (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20120028970-A1 | HETEROARYLTHIOMETHYL PYRIDINE DERIVATIVE | MSD K.K. (JP) | 2012-02-02 | — | — | US | disclosed |
| WO-2012007883-A1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20110015181-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
| EP-2264026-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010126163-A1 | HETEROARYLTHIOMETHYL PYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-11-04 | — | — | WO | disclosed |
| EP-1749014-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2010-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010207-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | ALDH1A1 643/4885HRH3 1001/4885ARG1 3788/4885 |
| US-20120028970-A1 | HETEROARYLTHIOMETHYL PYRIDINE DERIVATIVE | AR, NR5A1, ARL1 | ALDH1A1 219/4885HRH3 1523/4885ARG1 1802/4885 |
| US-20130281694-A1 | METHOD FOR PREPARING ROSUVASTATIN SALTS | HMGCR, SIRT5, CYP3A5 | ALDH1A1 1094/4885HRH3 3039/4885ARG1 4651/4885 |
| US-20110015181-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | NPY4R, NPY1R, NPY2R | ALDH1A1 4371/4885HRH3 119/4885ARG1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.